{"id":6583,"date":"2019-07-11T13:43:13","date_gmt":"2019-07-11T11:43:13","guid":{"rendered":"https:\/\/profertil.eu\/etudes\/l-carnitine-study-2016\/"},"modified":"2023-10-09T12:21:48","modified_gmt":"2023-10-09T10:21:48","slug":"l-carnitine-study-2016","status":"publish","type":"page","link":"https:\/\/profertil.eu\/fr\/etudes\/l-carnitine-study-2016\/","title":{"rendered":"\u00c9tude L-carnitine 2016"},"content":{"rendered":"\n
\"\"
\n

COMPOSITION
EXCEPTIONNELLE<\/span><\/h1>\n<\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\"\"<\/figure><\/div>\n\n\n\n

\u00bbEn raison de son effet synergique, la formule brevet\u00e9e PROfertil\u00ae<\/sup> est nettement sup\u00e9rieure \u00e0 l\u2019apport de L-carnitine \u00e0 forte dose.\u00ab <\/p>\n\n\n\n

<\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
<\/div>\n\n\n\n

\u00c9TUDE L-CARNITINE 2016<\/p>\n\n\n\n

Changement relatif des param\u00e8tres des spermatozo\u00efdes (en%) apr\u00e8s 3 mois de prise PROFERTIL\u00ae<\/sup> par rapport au groupe de mono substance<\/h3>\n<\/div>\n\n\n\n
\n
\"\"<\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n
<\/div>\n\n\n\n

Nombre de patients : 
<\/strong><\/strong>n = 299 
(groupe PROFERTIL\u00ae<\/sup>: n = 143; 
groupe de contr\u00f4le: n = 156)

Publication:
<\/strong>Reprod Biol Endocrin (Dec 2016) 14:84.<\/p>\n\n\n\n

<\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
La premi\u00e8re \u00e9tude prospective contr\u00f4l\u00e9e (par rapport \u00e0 la L-Carnitine \u00e0 forte dose) a montr\u00e9 la sup\u00e9riorit\u00e9 de la composition de PROFERTIL<\/strong>\u00ae<\/sup>:<\/strong><\/h6>\n\n\n\n